Hikma to buy sterile injectables maker Custopharm for $375m
Through the acquisition, Hikma will benefit from Custopharm’s 13 regulatory approved products, R&D professionals and a laboratory in…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
27 Sep 21
Through the acquisition, Hikma will benefit from Custopharm’s 13 regulatory approved products, R&D professionals and a laboratory in…
27 Sep 21
The US regulatory agency approved Repatha based on results from HAUSER-RCT study, which showed a significant reduction in…
24 Sep 21
The collaboration is structured to optimise and validate VaxEquity’s saRNA platform and use it to advance novel therapeutic…
23 Sep 21
The US regulator authorised the third dose of Comirnaty based on review by its Vaccines and Related Biological…
23 Sep 21
In exchange for the investment, Serum Life Sciences will subscribe for 3,382,950 new ordinary shares of Oxford Biomedica
22 Sep 21
Novartis said that the acquisition is in line with its strategy of finding treatments for patients with vision…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
22 Sep 21
The new API manufacturing facility for small molecules will be constructed at the Alexion Campus in College Park…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
21 Sep 21
Byooviz is said to be the first ophthalmology biosimilar for Lucentis to receive FDA approval and was previously…
21 Sep 21
In the trial, Comirnaty showed a neutralising antibody geometric mean titre (GMT) of 1,197.6 in children aged five…
20 Sep 21
The advisory committee has recommended booster dose of Pfizer and BioNTech’s mRNA Covid-19 vaccine Comirnaty in people aged…